Xiaogang Xiang1, Dechun Feng2, Seonghwan Hwang2, Tianyi Ren2, Xiaolin Wang2, Eszter Trojnar3, Csaba Matyas3, Ruidong Mo4, Dabao Shang4, Yong He2, Wonhyo Seo2, Vijay H Shah5, Pal Pacher3, Qing Xie6, Bin Gao7. 1. Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, 20892, USA; Department of Infectious Diseases, Translational Laboratory of Liver Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. 2. Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, 20892, USA. 3. Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD 20892, USA. 4. Department of Infectious Diseases, Translational Laboratory of Liver Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. 5. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. 6. Department of Infectious Diseases, Translational Laboratory of Liver Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. Electronic address: xieqingrjh@163.com. 7. Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, 20892, USA. Electronic address: bgao@mail.nih.gov.
Abstract
BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF) is a clinical syndrome defined by liver failure on pre-existing chronic liver disease. It is often associated with bacterial infection and high short-term mortality. Experimental models that fully reproduce ACLF are lacking, so too are effective pharmacological therapies for this condition. METHODS: To mimic ACLF conditions, we developed a severe liver injury model by combining chronic injury (chronic carbon tetrachloride [CCl4] injection), acute hepatic insult (injection of a double dose of CCl4), and bacterial infection (intraperitoneal injection of bacteria). Serum and liver samples from patients with ACLF or acute drug-induced liver injury (DILI) were used. Liver injury and regeneration were assessed to ascertain the potential benefits of interleukin-22 (IL-22Fc) administration. RESULTS: This severe liver injury model recapitulated some of the key features of clinical ACLF, including acute-on-chronic liver injury, bacterial infection, multi-organ injury, and high mortality. Liver regeneration in this model was severely impaired because of a shift from the activation of the pro-regenerative IL-6/STAT3 pathway to the anti-regenerative IFN-γ/STAT1 pathway. The impaired IL-6/STAT3 activation was due to the inability of Kupffer cells to produce IL-6; whereas the enhanced STAT1 activation was due to a strong innate immune response and subsequent production of IFN-γ. Compared to patients with DILI, patients with ACLF had higher levels of IFN-γ but lower liver regeneration. IL-22Fc treatment improved survival in ACLF mice by reversing the STAT1/STAT3 pathway imbalance and enhancing expression of many antibacterial genes in a manner involving the anti-apoptotic protein BCL2. CONCLUSIONS: Acute-on-chronic liver injury or bacterial infection is associated with impaired liver regeneration due to a shift from a pro-regenerative to an anti-regenerative pathway. IL-22Fc therapy reverses this shift and attenuates bacterial infection, thus IL-22Fc may have therapeutic potential for ACLF treatment. LAY SUMMARY: A mouse model combining chronic liver injury, acute hepatic insult, and bacterial infection recapitulates some of the key features of acute-on-chronic liver failure (ACLF) in patients. Both fibrosis and bacterial infection contribute to the impaired regenerative capacity of the liver in patients with ACLF. Herein, we show that IL-22Fc therapy improves ACLF by reprogramming impaired regenerative pathways and attenuating bacterial infection. Thus, it may have therapeutic potential for patients with ACLF. Published by Elsevier B.V.
BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF) is a clinical syndrome defined by liver failure on pre-existing chronic liver disease. It is often associated with bacterial infection and high short-term mortality. Experimental models that fully reproduce ACLF are lacking, so too are effective pharmacological therapies for this condition. METHODS: To mimic ACLF conditions, we developed a severe liver injury model by combining chronic injury (chronic carbon tetrachloride [CCl4] injection), acute hepatic insult (injection of a double dose of CCl4), and bacterial infection (intraperitoneal injection of bacteria). Serum and liver samples from patients with ACLF or acute drug-induced liver injury (DILI) were used. Liver injury and regeneration were assessed to ascertain the potential benefits of interleukin-22 (IL-22Fc) administration. RESULTS: This severe liver injury model recapitulated some of the key features of clinical ACLF, including acute-on-chronic liver injury, bacterial infection, multi-organ injury, and high mortality. Liver regeneration in this model was severely impaired because of a shift from the activation of the pro-regenerative IL-6/STAT3 pathway to the anti-regenerative IFN-γ/STAT1 pathway. The impaired IL-6/STAT3 activation was due to the inability of Kupffer cells to produce IL-6; whereas the enhanced STAT1 activation was due to a strong innate immune response and subsequent production of IFN-γ. Compared to patients with DILI, patients with ACLF had higher levels of IFN-γ but lower liver regeneration. IL-22Fc treatment improved survival in ACLF mice by reversing the STAT1/STAT3 pathway imbalance and enhancing expression of many antibacterial genes in a manner involving the anti-apoptotic protein BCL2. CONCLUSIONS: Acute-on-chronic liver injury or bacterial infection is associated with impaired liver regeneration due to a shift from a pro-regenerative to an anti-regenerative pathway. IL-22Fc therapy reverses this shift and attenuates bacterial infection, thus IL-22Fc may have therapeutic potential for ACLF treatment. LAY SUMMARY: A mouse model combining chronic liver injury, acute hepatic insult, and bacterial infection recapitulates some of the key features of acute-on-chronic liver failure (ACLF) in patients. Both fibrosis and bacterial infection contribute to the impaired regenerative capacity of the liver in patients with ACLF. Herein, we show that IL-22Fc therapy improves ACLF by reprogramming impaired regenerative pathways and attenuating bacterial infection. Thus, it may have therapeutic potential for patients with ACLF. Published by Elsevier B.V.
Authors: Juan P Arab; Tejasav S Sehrawat; Douglas A Simonetto; Vikas K Verma; Dechun Feng; Tom Tang; Kevin Dreyer; Xiaoqiang Yan; William L Daley; Arun Sanyal; Naga Chalasani; Svetlana Radaeva; Liu Yang; Hugo Vargas; Mauricio Ibacache; Bin Gao; Gregory J Gores; Harmeet Malhi; Patrick S Kamath; Vijay H Shah Journal: Hepatology Date: 2020-04-27 Impact factor: 17.425
Authors: Javier Fernández; Juan Acevedo; Reiner Wiest; Thierry Gustot; Alex Amoros; Carme Deulofeu; Enric Reverter; Javier Martínez; Faouzi Saliba; Rajiv Jalan; Tania Welzel; Marco Pavesi; María Hernández-Tejero; Pere Ginès; Vicente Arroyo Journal: Gut Date: 2017-08-28 Impact factor: 23.059
Authors: Vairappan Balasubramaniyan; Dipok Kumar Dhar; Anne E Warner; Wai-Yin Vivien Li; Azin Farzan Amiri; Beverley Bright; Rajeshwar P Mookerjee; Nathan A Davies; David L Becker; Rajiv Jalan Journal: J Hepatol Date: 2013-01-29 Impact factor: 25.083
Authors: Thomas G Bird; Miryam Müller; Luke Boulter; David F Vincent; Rachel A Ridgway; Elena Lopez-Guadamillas; Wei-Yu Lu; Thomas Jamieson; Olivier Govaere; Andrew D Campbell; Sofía Ferreira-Gonzalez; Alicia M Cole; Trevor Hay; Kenneth J Simpson; William Clark; Ann Hedley; Mairi Clarke; Pauline Gentaz; Colin Nixon; Steven Bryce; Christos Kiourtis; Joep Sprangers; Robert J B Nibbs; Nico Van Rooijen; Laurent Bartholin; Steven R McGreal; Udayan Apte; Simon T Barry; John P Iredale; Alan R Clarke; Manuel Serrano; Tania A Roskams; Owen J Sansom; Stuart J Forbes Journal: Sci Transl Med Date: 2018-08-15 Impact factor: 17.956